The Use of Transcranial Direct Current Stimulation (tDCS) in Adults With Developmental Disabilities
tDCS-RIADD
1 other identifier
interventional
60
1 country
1
Brief Summary
Aggressive behaviours are highly prevalent among people with developmental disabilities, both in community and inpatient or residential settings, with adverse consequences for the individuals involved and others. Some predictive factors, particularly impulsivity, are dynamic with neurobiological underpinnings, and as such amenable to change or neuromodulation using non-invasive brain stimulation techniques. With this in mind, we designed an experimental protocol to determine the efficacy of transcranial Direct Current Stimulation (tDCS) as a non-invasive brain stimulation technique to reduce impulsivity and aggression associated with developmental disability.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Sep 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 27, 2020
CompletedFirst Posted
Study publicly available on registry
February 1, 2021
CompletedStudy Start
First participant enrolled
September 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2028
ExpectedMarch 25, 2025
March 1, 2025
3.1 years
November 27, 2020
March 21, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Aggression
To determine the effect of tDCS treatment on aggressive symptoms measured by The Modified Overt Aggression Scale (MOAS); Total weighted scores range from 0-40, with a higher score indicating more aggressive behavior.
change from baseline one week and one month after the third tDCS session
Secondary Outcomes (5)
Maladaptive behaviors
change from baseline one week and one month after the third tDCS session
Intervention side effects
Up to 72hrs after the first, second, and third active or sham tDCS treatments.
Trait Impulsivity
Baseline
Impulsivity
change from baseline and the same day after the third tDCS sessions
Treatment Acceptability
Up to 72hrs after the third active or sham tDCS treatments.
Study Arms (2)
Active tDCS
ACTIVE COMPARATORTranscranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the stimulation using two sponge electrodes soaked in a saline solution. The stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The active stimulation condition will use a constant current of 2mA, delivered via gradual increase and decrease over 10 seconds at the onset and offset of stimulation (current ramps), respectively. The duration a single tDCS session will be 20 minutes.
Sham tDCS
SHAM COMPARATORSham Transcranial Direct Current Stimulation: Soterix tDCS kit will be used to deliver the sham stimulation using two sponge electrodes soaked in a saline solution. The sham stimulation montage will comprise of left anodal Dorsal Lateral Prefrontal cortex (DLPFC) stimulation for 10s only. The anodal electrode will be placed over the area corresponding to the left DLPFC (F5 of the EEG10-20 international system) and the reference (cathodal) electrode over the right supraorbital ridge. The sham tDCS is identical to the active tDCS except that the current will be delivered only in the first 10 seconds, after which the stimulation will cease but with the electrodes still in place throughout the session. The duration of each sham tDCS session will be 20 minutes.
Interventions
Eligibility Criteria
You may qualify if:
- Adults aged 18-64 years
- Diagnosis of a developmental disability
- History of one or more incidents of aggression in the last month
- Consent to participate in the trial by the individual or their Substitute Decision Maker
You may not qualify if:
- History of epilepsy or seizures
- History of acquired brain injury
- Having metal in the brain/skull, e.g. splinters, fragments or clips
- Having a cochlear implant
- Having an implanted neuro-stimulator (e.g. direct brain stimulation, epidural/subdural stimulation, vagal nerve stimulation)
- History of brain surgery of procedure
- History of severe adverse reaction to tDCS
- Having a cardiac pacemaker or intracardiac lines
- Current alcohol or drug misuse
- Having a sensitive scalp
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Providence Care Hospital
Kingston, Ontario, K7L 4X3, Canada
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Muhammad Ayub, MD
Queen's University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Principle Investigator
Study Record Dates
First Submitted
November 27, 2020
First Posted
February 1, 2021
Study Start
September 1, 2022
Primary Completion
September 30, 2025
Study Completion (Estimated)
December 31, 2028
Last Updated
March 25, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF
- Time Frame
- All IPD will be available at study end (in two years) and be available for five years following study end date.
- Access Criteria
- Designated study personnel only
All collected IPD including all IPD that underlie results in publication.